Company profile
Alethia BioTherapeutics company profile
Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates the response to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface..... For more information, log in to dureach.com to view the full company profile.
Business identity
- Website
- http://www.alethiabio.com
- Contact email
- [email protected]
- Phone number
- 514-858-7666
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00011-00050 employees
- Revenue range
- $10K+
- Founded
- 2002-01-01
Headquarters
- Headquarters
- Maple Bay, British Columbia, Canada
- Postal code
- H2X 1Y4
- Country code
- CA
- Continent
- North America